MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- ABBOTT INDIA - MYLAN (US)
ABBOTT INDIA vs MYLAN (US) - Comparison Results
ABBOTT INDIA Change
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 ABBOTT INDIA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ABBOTT INDIA Mar-19 |
MYLAN Dec-18 |
ABBOTT INDIA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 8,834 | 3,561 | - | |
| Low | Rs | 5,458 | 1,960 | - | |
| Sales per share (Unadj.) | Rs | 1,731.1 | 1,638.8 | - | |
| Earnings per share (Unadj.) | Rs | 211.9 | 44.5 | - | |
| Cash flow per share (Unadj.) | Rs | 219.9 | 351.3 | - | |
| Dividends per share (Unadj.) | Rs | 65.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.9 | 0 | - | |
| Book value per share (Unadj.) | Rs | 945.2 | 1,772.8 | - | |
| Shares outstanding (eoy) | m | 21.25 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.1 | 1.7 | 245.0% | |
| Avg P/E ratio | x | 33.7 | 62.0 | 54.3% | |
| P/CF ratio (eoy) | x | 32.5 | 7.9 | 413.6% | |
| Price / Book Value ratio | x | 7.6 | 1.6 | 485.5% | |
| Dividend payout | % | 30.7 | 0 | - | |
| Avg Mkt Cap | Rs m | 151,848 | 1,420,461 | 10.7% | |
| No. of employees | `000 | 3.5 | 35.0 | 10.0% | |
| Total wages/salary | Rs m | 4,356 | 0 | - | |
| Avg. sales/employee | Rs Th | 10,555.5 | 24,089.9 | 43.8% | |
| Avg. wages/employee | Rs Th | 1,249.9 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,292.2 | 654.1 | 197.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 36,786 | 843,147 | 4.4% | |
| Other income | Rs m | 1,133 | 0 | - | |
| Total revenues | Rs m | 37,919 | 843,147 | 4.5% | |
| Gross profit | Rs m | 6,047 | 218,175 | 2.8% | |
| Depreciation | Rs m | 169 | 157,870 | 0.1% | |
| Interest | Rs m | 23 | 40,552 | 0.1% | |
| Profit before tax | Rs m | 6,989 | 19,752 | 35.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 2,485 | -3,142 | -79.1% | |
| Profit after tax | Rs m | 4,503 | 22,895 | 19.7% | |
| Gross profit margin | % | 16.4 | 25.9 | 63.5% | |
| Effective tax rate | % | 35.6 | -15.9 | -223.5% | |
| Net profit margin | % | 12.2 | 2.7 | 450.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 27,610 | 470,812 | 5.9% | |
| Current liabilities | Rs m | 8,569 | 343,274 | 2.5% | |
| Net working cap to sales | % | 51.8 | 15.1 | 342.2% | |
| Current ratio | x | 3.2 | 1.4 | 234.9% | |
| Inventory Days | Days | 60 | 84 | 72.0% | |
| Debtors Days | Days | 27 | 93 | 29.4% | |
| Net fixed assets | Rs m | 1,057 | 163,557 | 0.6% | |
| Share capital | Rs m | 213 | 449 | 47.3% | |
| Net worth | Rs m | 20,086 | 912,131 | 2.2% | |
| Long term debt | Rs m | 0 | 984,482 | 0.0% | |
| Total assets | Rs m | 29,409 | 2,446,689 | 1.2% | |
| Interest coverage | x | 311.6 | 1.5 | 20,953.7% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
| Sales to assets ratio | x | 1.3 | 0.3 | 363.0% | |
| Return on assets | % | 15.4 | 2.6 | 593.4% | |
| Return on equity | % | 22.4 | 2.5 | 893.2% | |
| Return on capital | % | 34.9 | 3.2 | 1,097.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,991 | 175,206 | 2.8% | |
| From Investments | Rs m | -2,570 | -90,562 | 2.8% | |
| From Financial Activity | Rs m | -1,428 | -81,621 | 1.7% | |
| Net Cashflow | Rs m | 993 | 1,452 | 68.4% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.82 Rs / USD
Compare ABBOTT INDIA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ABBOTT INDIA With: DR. DATSONS LABS TORRENT PHARMA PANACEA BIOTECH VENUS REMEDIES BIOCON
Today's Market
Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views On News
ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)
Aug 18, 2020 | Updated on Aug 18, 2020For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
An India Revival Stock I'm Bullish On... (Profit Hunter)
Apr 9, 2021This could take India to the position of 3rd largest economy.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
More
